P2Y4 Inhibitors

P2Y4 inhibitors consist of a range of compounds that modulate the activity of the P2Y4 receptor, a GPCR responsive to uridine nucleotides. P2Y4 plays roles in various physiological processes, including vascular regulation, immune responses, and neurotransmission. The majority of these inhibitors are non-selective, affecting multiple P2Y receptor subtypes, but a few, like MRS 4062, MRS 4067, and MRS 4506, show selective inhibition towards P2Y4.

The inhibitors listed exhibit a range of mechanisms in modulating P2Y4 activity. Compounds like Suramin and Reactive Blue 2 are broad-spectrum P2 receptor antagonists, affecting multiple subtypes including P2Y4. Their non-selectivity requires cautious interpretation of results when used in experimental setups focusing on P2Y4. PPADS and its derivative are more selective and have been used in studies to differentiate the roles of various P2Y receptors, including P2Y4. The MRS series, including MRS 4062, MRS 4067, and MRS 4506, represent a more focused approach to inhibiting P2Y4. These compounds are designed to selectively antagonize P2Y4, making them valuable tools for studying the specific functions and signaling pathways associated with this receptor. Their selective inhibition provides a clearer understanding of P2Y4's role in physiological and pathological processes.